

27. Zia Q, Mohammad O, Rauf MA, Khan W, Zubair S. Biomimetically engineered amphotericin b nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals. *Sci rep* 2017;7(1):1-19. [doi:10.1038/s41598-017-11847-0](https://doi.org/10.1038/s41598-017-11847-0)
28. Soltani S, Zakeri-Milani P, Barzegar-Jalali M, Jelvehgari M. Fabrication and in-vitro evaluation of ketotifen fumarate-loaded plga nanoparticles as a sustained delivery system. *Iran j pharm res* 2017;16(1):22. <https://www.nih.gov/coronavirus>
29. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin b-loaded engineered plga nanoparticles. *Pharm res* 2009;26(12):2588-98. [doi:10.1007/s11095-009-9973-4](https://doi.org/10.1007/s11095-009-9973-4)
30. Cartaxo AL, Costa-Pinto AR, Martins A, Faria S, Gonçalves VM, Tiritan ME, et al. Influence of pdla nanoparticles size on drug release and interaction with cells. *J Biomed Mater Res A* 2019;107(3):482-93. [doi:10.1002/jbm.a.36563](https://doi.org/10.1002/jbm.a.36563)

Figures captions

Fig.1. FT-IR of the PLGA (a), PEG (b), GalN (c), PEG-Succinic anhydride (d), PEG-Succinic anhydride-GalN (e), and PEG-Succinic anhydride- GalN-PLGA (f)

Fig.2. ¹H-NMR of the PLGA (a), PEG (b), PEG-Succinic anhydride (c), PEG-Succinic anhydride-GalN (d), and PEG- Succinic anhydride- GalN-PLGA (e)

Fig.3. SEM image of Amphotericin B-loaded PLGA NPs (a) and Amphotericin B-loaded PLGA-GalN (b) NPs with the drug to polymer ratio of 1:6

Fig.4. DSC curve of the intact Amphotericin B powder (a), PLGA(b), NPs of drug: PLGA 1:1 (c), physical mixture of drug: PLGA 1:1 (d), NPs of drug: PLGA 1:3 (e), physical mixture of drug: PLGA 1:3 (f), NPs of drug: PLGA 1:6 (g), physical mixture of drug: PLGA 1:6 (h), and NPs of drug: PLGA-GalN 1:6(i)

Fig.5. Powder X-ray diffraction of intact Amphotericin B powder (a), PLGA (b), Amphotericin B-loaded NPs with the drug PLGA ratio of 1:3 (c), 1:6 (d), and Amphotericin B-loaded NPs with the drug PLGA-GalN ratio of 1:6 (e)

Fig.6. Dissolution profiles of intact Amphotericin B powder (a) and Amphotericin B-loaded NPs with drug to PLGA ratio of 1:1 (b), 1:3 (c), 1:6 (d), and drug to PLGA-GalN ratio of 1:6b (e)

Tables**Table 1**

Polydispersity (\pm SD), mean (\pm SD) particle diameter, zeta potential, encapsulation efficiency (\pm SD), and production yield of the various PLGA and PLGA-GalN NPs.

Formulations	Polydispersity	Mean particle size (nm)	Zeta potential (Mv)	Encapsulation efficiency (%)	Production yield (%)
1:1 Drug:PLGA	0.21 \pm 0.03	238.2 \pm 7.59	- 0.231	68.185% \pm 1.9	67 %
1:3 Drug:PLGA	0.24 \pm 0.014	174.46 \pm 3.49	- 0.285	75.69% \pm 0.4	72 %
1:6 Drug:PLGA	0.13 \pm 0.012	174.1 \pm 4.188	0.365-	73.05 % \pm 0.6	77 %
1:6 Drug:PLGA-GalN	0.286 \pm 0.03	255.6 \pm 4.0819	- 0.456	75.04 \pm 0.95	71 %







